Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPHIMMUN: Avelumab in chemo-resistant gestational trophoblastic neoplasias
2016-002322-37Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in trophoblastic tumour, sponsored by Hospices Civils de Lyon. Primary endpoint: Rate of patients with successful normalization of hCG allowing for treatment discontinuation. Started Dec 2016; status: active.
02
Drugs
avelumab
03
Conditions
trophoblastic tumour
Beyond the preview
Go deeper on 2016-002322-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002322-37.